Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Major depressive disorder (MDD) significantly impairs patient functioning.
• Previous treatments for MDD have shown varying success in restoring function.
• Understanding the relationship between symptom reduction and functional improvement is crucial.

Purpose of the Study:

• To analyze the impact of remission versus response status on functional outcomes in MDD patients.
• To compare functional status across different levels of depressive symptom reduction.
• To investigate the correlation between treatment efficacy and patient functioning.

Main Methods:

• Post-hoc analysis of two randomized trials involving patients with treatment-resistant MDD.
• Patients received open-label escitalopram, fluoxetine, paroxetine-CR, sertraline, or venlafaxine-XR, followed by double-blind adjunctive placebo or aripiprazole.
• Functional status was measured using the Sheehan Disability Scale; remission was defined as >=50% Montgomery-Asberg Depression Rating Scale (MADRS) score reduction with MADRS <=10.

Main Results:

• Patients in remission (144/679) showed significantly greater functional improvements than those responding without remission (44/679) or non-responders (491/679).
• Symptomatic efficacy (Hamilton Rating Scale for Depression) did not significantly correlate with functional outcomes.
• Remission status was a stronger predictor of functional improvement than response alone.

Conclusions:

• Symptomatic remission in MDD is associated with substantially better functional recovery compared to partial response.
• Functional improvement may be a distinct outcome from symptom reduction in MDD treatment.
• Therapeutic strategies aiming for high remission rates may optimize patient functioning beyond mere symptom control.